NCT05717530

Brief Summary

Laparoscopic cholecystectomy is one of the most common operations in abdominal surgery. Effective analgesia in the postoperative period; It is of great importance in terms of acceleration of recovery, prevention of atelectasis, reduction of endocrine and metabolic stress response, reduction of thromboembolic complications, protection of cognitive functions, prevention of chronic pain development, and reduction of hospital stay . Intravenous paracetamol, NSAID/cyclooxygenase-2 selective inhibitors, opioids, local anesthetic infiltration in the port area, intraperitoneal local anesthetic insufflation or plan blocks can be used in the treatment of postoperative pain after laparoscopic cholecystectomy. Operation, tissue trauma, anesthesia, drugs given to the patient, type of anesthesia, blood loss, temperature changes and pain cause postoperative stress response

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Feb 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 24, 2023

Completed
15 days until next milestone

First Posted

Study publicly available on registry

February 8, 2023

Completed
7 days until next milestone

Study Start

First participant enrolled

February 15, 2023

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2023

Completed
6 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 7, 2023

Completed
Last Updated

January 29, 2025

Status Verified

January 1, 2025

Enrollment Period

4 months

First QC Date

January 24, 2023

Last Update Submit

January 27, 2025

Conditions

Keywords

Cholecystectomy, LaparoscopicErector spinae plane blockanalgesiacortisolprolactin

Outcome Measures

Primary Outcomes (1)

  • Stress hormone response

    Blood was taken and recorded in a yellow capped gel biochemistry tube (SSTTM II Advance Tubes) for the measurement of stress hormone glucose(70-100 mg/dl), prolactin(4.79-23.3µg/dL), and cortisol(60.2-184 µg/dL) 1 hour before and 1 hour after the operation.

    5 hour

Secondary Outcomes (2)

  • Visual Analog Pain Scale

    24 hour

  • Analgesia period

    24 hour

Study Arms (3)

wound site local anesthesic infiltration

ACTIVE COMPARATOR

at the end of the operation; 0.5% bupivacaine (1mg/kg) was infiltrated into the fascia muscles and preperitoneal space in equal doses to the wound at the 4 trocar entry site

Procedure: wound site local anesthesic infiltration

Erector spinae plane block

ACTIVE COMPARATOR

: Erector spina block was applied to the group, after the end of the operation, the patients were placed in the left lateral decubitus position and the spinous process of the 8th thoracic vertebra was marked under sterile conditions. After visualizing the spinous process with ultrasound (EsoateMyLab™30 Gold, 8-18 MHz, Genova, Italy), the linear probe (8-12 MHz) was shifted 3 cm laterally from the midline in the cranial-caudal direction. Trapezius, erector spinae muscles, transverse process and pleura were visualized, and 20ml of 0.25% bupivacaine was injected into the validated interval by directing the peripheral nerve block needle in the cranio-caudal direction

Procedure: Erector spina plane block

Control

NO INTERVENTION

There was no intervention.

Interventions

: at the end of the operation; 0.5% bupivacaine (1mg/kg) was infiltrated into the fascia muscles and preperitoneal space in equal doses to the wound at the 4 trocar entry site.

wound site local anesthesic infiltration

Erector spina block was applied to the group, after the end of the operation, the patients were placed in the left lateral decubitus position and the spinous process of the 8th thoracic vertebra was marked under sterile conditions. After visualizing the spinous process with ultrasound (EsoateMyLab™30 Gold, 8-18 MHz, Genova, Italy), the linear probe (8-12 MHz) was shifted 3 cm laterally from the midline in the cranial-caudal direction. Trapezius, erector spinae muscles, transverse process and pleura were visualized, and 20ml of 0.25% bupivacaine was injected into the validated interval by directing the peripheral nerve block needle in the cranio-caudal direction.

Erector spinae plane block

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • who will undergo laparoscopic cholecystectomy
  • ASA (American Society of Anesthesiology) I-II
  • age group
  • operated between 08:00-12:00 in the morning

You may not qualify if:

  • Pregnant,
  • Diabetes Mellitus
  • Emergency surgery
  • ASA (American Society of Anesthesiology)III-IV
  • Patients who did not consent to the study,
  • History of local anesthetic allergy,
  • Coagulation disorder,
  • Morbid obesity (body mass index \>40 kg/m²),
  • Severe organ failure,
  • Previous neurological deficit,
  • Psychiatric disease,
  • Patients with a history of chronic pain
  • Who were switched to the open procedure due to surgical complications during the operation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sisli Hamidiye Etfal Training and Research Hospital

Şişli, Istanbul, 34376, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Pain, PostoperativeHernia, InguinalAgnosia

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and SymptomsHernia, AbdominalHerniaPathological Conditions, AnatomicalPerceptual DisordersNeurobehavioral ManifestationsNervous System Diseases

Study Officials

  • murat sahin

    şişli etfal eğitim araştırma hastanesi

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principal investigator

Study Record Dates

First Submitted

January 24, 2023

First Posted

February 8, 2023

Study Start

February 15, 2023

Primary Completion

June 1, 2023

Study Completion

June 7, 2023

Last Updated

January 29, 2025

Record last verified: 2025-01

Data Sharing

IPD Sharing
Will not share

Locations